TTY Biopharm Company Limited

NT$79.20As of Sun 8 Nov 2026, 12:00 UTC
TPEx:4105Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR 0.78%
Div yield 5.68%
ROE 22.52%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.08
PE TTM 11.89
TSR TTM 5.56%
Mkt cap NT$19.69B
ROIC 21.78%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$84
6.22%
(81.19%)
Hold 2|9|12|4|12
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
1.16
1.25
1.24
1.32
29.12%
30.06%
20.74%
24.32%
RevenueNT$B
1.748
1.751
1.709
1.742
7.72%
3.46%
3.20%
2.19%
Peers (US$594.8M)
Cap (US$)
PE
673.7M
22.18x
595.9M
32.54x
Capital
TTM
5Y
10Y
Leveragex
1.009
(0.050)
(0.048)
EBIT/Intx
0.472
0.180
0.186
Own earn%
(95.57)
22.40
27.60
Sh yield%
44.12
20.93
18.84
Owners
Insiders/Inst%
8.45
79.96
Short interest%
3.19
SBC / revenue%
3.37
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
20
Op margin range%
4–14
$1 testx
—
Incr. ROIC%
12